JP2020532981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532981A5 JP2020532981A5 JP2020512843A JP2020512843A JP2020532981A5 JP 2020532981 A5 JP2020532981 A5 JP 2020532981A5 JP 2020512843 A JP2020512843 A JP 2020512843A JP 2020512843 A JP2020512843 A JP 2020512843A JP 2020532981 A5 JP2020532981 A5 JP 2020532981A5
- Authority
- JP
- Japan
- Prior art keywords
- cedna vector
- cedna
- vector according
- stem
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 91
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 241000238631 Hexapoda Species 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 241000702421 Dependoparvovirus Species 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000002539 nanocarrier Substances 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 4
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 4
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 4
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 4
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 4
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 4
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 4
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 4
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 4
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
- -1 IncRNA Proteins 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 230000007488 abnormal function Effects 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 4
- 241000701945 Parvoviridae Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022176371A JP2022190081A (ja) | 2017-09-08 | 2022-11-02 | 修飾型閉端dna(cedna) |
| JP2024189111A JP2025010253A (ja) | 2017-09-08 | 2024-10-28 | 修飾型閉端dna(cedna) |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556281P | 2017-09-08 | 2017-09-08 | |
| US201762556335P | 2017-09-08 | 2017-09-08 | |
| US201762556324P | 2017-09-08 | 2017-09-08 | |
| US201762556319P | 2017-09-08 | 2017-09-08 | |
| US201762556329P | 2017-09-08 | 2017-09-08 | |
| US201762556331P | 2017-09-08 | 2017-09-08 | |
| US62/556,329 | 2017-09-08 | ||
| US62/556,335 | 2017-09-08 | ||
| US62/556,319 | 2017-09-08 | ||
| US62/556,331 | 2017-09-08 | ||
| US62/556,324 | 2017-09-08 | ||
| US62/556,281 | 2017-09-08 | ||
| PCT/US2018/049996 WO2019051255A1 (en) | 2017-09-08 | 2018-09-07 | CLOSED-ENDED DNA (CEDNA) MODIFIED |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176371A Division JP2022190081A (ja) | 2017-09-08 | 2022-11-02 | 修飾型閉端dna(cedna) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532981A JP2020532981A (ja) | 2020-11-19 |
| JP2020532981A5 true JP2020532981A5 (enExample) | 2021-10-21 |
Family
ID=65635235
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512843A Pending JP2020532981A (ja) | 2017-09-08 | 2018-09-07 | 修飾型閉端dna(cedna) |
| JP2022176371A Pending JP2022190081A (ja) | 2017-09-08 | 2022-11-02 | 修飾型閉端dna(cedna) |
| JP2024189111A Pending JP2025010253A (ja) | 2017-09-08 | 2024-10-28 | 修飾型閉端dna(cedna) |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176371A Pending JP2022190081A (ja) | 2017-09-08 | 2022-11-02 | 修飾型閉端dna(cedna) |
| JP2024189111A Pending JP2025010253A (ja) | 2017-09-08 | 2024-10-28 | 修飾型閉端dna(cedna) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200283794A1 (enExample) |
| EP (1) | EP3678710A4 (enExample) |
| JP (3) | JP2020532981A (enExample) |
| KR (1) | KR20200051011A (enExample) |
| CN (1) | CN111132699A (enExample) |
| AU (1) | AU2018327348A1 (enExample) |
| BR (1) | BR112020004151A2 (enExample) |
| CA (1) | CA3075168A1 (enExample) |
| IL (1) | IL272797A (enExample) |
| MA (1) | MA50100A (enExample) |
| MX (1) | MX2020002500A (enExample) |
| PH (1) | PH12020500465A1 (enExample) |
| SG (1) | SG11202000698SA (enExample) |
| UA (1) | UA129010C2 (enExample) |
| WO (1) | WO2019051255A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| JP7374883B2 (ja) | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子およびその使用 |
| US20220290186A1 (en) * | 2017-12-06 | 2022-09-15 | Generation Bio Co. | Gene editing using a modified closed-ended dna (cedna) |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| KR20200120649A (ko) * | 2018-02-14 | 2020-10-21 | 제너레이션 바이오 컴퍼니 | 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도 |
| CN119955796A (zh) | 2018-08-09 | 2025-05-09 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用于非病毒基因疗法的用途 |
| BR112021007102A2 (pt) * | 2018-11-09 | 2021-08-03 | Generation Bio Co. | dna com extremidade fechada modificada (cedna) que compreende repetições terminais invertidas modificadas simétricas |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| US20220220488A1 (en) * | 2019-07-17 | 2022-07-14 | Generation Bio Co. | Synthetic production of single-stranded adeno associated viral dna vectors |
| WO2021011840A1 (en) * | 2019-07-17 | 2021-01-21 | Generation Bio Co. | Compositions and production of nicked closed-ended dna vectors |
| WO2021030745A1 (en) * | 2019-08-15 | 2021-02-18 | The Children's Hospital Of Philadelphia | Combined transgene and intron-derived mirna therapy for treatment of sca1 |
| EP4025196A4 (en) * | 2019-09-06 | 2023-07-12 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
| JP2022549138A (ja) | 2019-09-18 | 2022-11-24 | インターガラクティック セラピューティクス インコーポレイテッド | 合成dnaベクターおよびその使用法 |
| WO2021072031A1 (en) * | 2019-10-11 | 2021-04-15 | Insideoutbio, Inc. | Methods and compositions for the manufacture and use of circular dna encoded therapeutics for genetic disorders and other diseases |
| WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| JP2023520764A (ja) * | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | 第ix因子治療薬を発現するための非ウイルス性dnaベクター及びその使用 |
| MX2022011806A (es) * | 2020-03-24 | 2023-01-11 | Generation Bio Co | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher. |
| CN115968280A (zh) * | 2020-05-18 | 2023-04-14 | 世代生物公司 | 新型脂质及其纳米颗粒组合物 |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| US20220243201A1 (en) * | 2020-08-23 | 2022-08-04 | Bioverativ Therapeutics Inc. | Engineered itr sequences and methods of use |
| CA3189673A1 (en) | 2020-08-23 | 2022-03-03 | Ajay MAGHODIA | Modified baculovirus system for improved production of closed-ended dna (cedna) |
| US20230383311A1 (en) * | 2020-09-16 | 2023-11-30 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| KR20230066615A (ko) * | 2020-09-16 | 2023-05-16 | 제너레이션 바이오 컴퍼니 | 폐쇄형 dna 벡터 및 페닐알라닌 히드록실라아제(pah) 발현을 위한 이의 용도 |
| GB202014751D0 (en) * | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Targeting vector |
| CA3211687A1 (en) * | 2021-03-19 | 2022-09-22 | Ozan ALKAN | Non-viral dna vectors and uses thereof for expressing pfic therapeutics |
| WO2022232029A2 (en) * | 2021-04-26 | 2022-11-03 | University Of Florida Research Foundation, Incorporated | Synthetic aav vectors for repeated delivery of therapeutic genes |
| AU2022264509A1 (en) * | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| EP4329884A1 (en) * | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| EP4333886A4 (en) * | 2021-05-07 | 2025-11-12 | Generation Bio Co | NON-VIRAL DNA VECTORS FOR VACCINE ADMINISTRATION |
| US20240261395A1 (en) * | 2021-05-07 | 2024-08-08 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| EP4419677A4 (en) * | 2021-10-18 | 2025-09-24 | Flagship Pioneering Innovations Vii Llc | DNA COMPOSITIONS AND RELATED METHODS |
| KR20240161965A (ko) | 2022-03-14 | 2024-11-13 | 제너레이션 바이오 컴퍼니 | 이종 프라임 부스트 백신 조성물 및 사용 방법 |
| CN117802161A (zh) * | 2022-06-30 | 2024-04-02 | 苏州吉恒基因科技有限公司 | 精准重组腺相关病毒载体及其用途 |
| WO2024040222A1 (en) * | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| WO2024182707A1 (en) | 2023-03-02 | 2024-09-06 | Krystal Biotech, Inc. | Interleukin-2 and interleukin-12 for cancer therapy |
| US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
| US11767541B1 (en) * | 2023-03-27 | 2023-09-26 | Genecraft, Inc. | Adeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer |
| US11891617B1 (en) * | 2023-03-27 | 2024-02-06 | Genecraft Inc. | Modified complex platform of adeno-associated virus with improved rate of expression of loaded genes and reduced genotoxicity |
| WO2024220969A2 (en) * | 2023-04-21 | 2024-10-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Novel transmembrane sensors and method of characterization for lysis-free detection of intracellular targets |
| WO2025114932A1 (en) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification of closed-ended dna molecules |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050019824A1 (en) * | 1994-03-08 | 2005-01-27 | Human Genome Sciences, Inc. | Fibroblast Growth Factor-10 |
| US20050026838A1 (en) * | 1995-06-05 | 2005-02-03 | Human Genome Sciences, Inc. | Fibroblast Growth Factor-13 |
| DE10044384A1 (de) * | 2000-09-08 | 2002-04-18 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| US20060166363A1 (en) * | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
| EP1979485A2 (en) * | 2006-01-31 | 2008-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| EP2866826B1 (en) * | 2012-06-27 | 2025-08-06 | Meiragtx UK II Limited | Combination for treating an inflammatory disorder |
| CN104087613B (zh) * | 2014-06-30 | 2017-08-29 | 中国科学院苏州生物医学工程技术研究所 | 基于aav‑itr的基因表达微载体及其构建方法和应用 |
| CA3011529A1 (en) * | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta t-cells |
| PT3423110T (pt) * | 2016-03-03 | 2021-11-09 | Univ Massachusetts | Adn em dúplex linear de extremidades fechadas para transferência génica não viral |
-
2018
- 2018-09-07 WO PCT/US2018/049996 patent/WO2019051255A1/en not_active Ceased
- 2018-09-07 BR BR112020004151-3A patent/BR112020004151A2/pt not_active Application Discontinuation
- 2018-09-07 MA MA050100A patent/MA50100A/fr unknown
- 2018-09-07 SG SG11202000698SA patent/SG11202000698SA/en unknown
- 2018-09-07 CN CN201880058155.7A patent/CN111132699A/zh active Pending
- 2018-09-07 AU AU2018327348A patent/AU2018327348A1/en not_active Abandoned
- 2018-09-07 US US16/644,568 patent/US20200283794A1/en not_active Abandoned
- 2018-09-07 KR KR1020207009737A patent/KR20200051011A/ko not_active Ceased
- 2018-09-07 JP JP2020512843A patent/JP2020532981A/ja active Pending
- 2018-09-07 MX MX2020002500A patent/MX2020002500A/es unknown
- 2018-09-07 EP EP18854941.4A patent/EP3678710A4/en active Pending
- 2018-09-07 UA UAA202000594A patent/UA129010C2/uk unknown
- 2018-09-07 CA CA3075168A patent/CA3075168A1/en active Pending
-
2020
- 2020-02-20 IL IL272797A patent/IL272797A/en unknown
- 2020-03-06 PH PH12020500465A patent/PH12020500465A1/en unknown
-
2022
- 2022-11-02 JP JP2022176371A patent/JP2022190081A/ja active Pending
-
2024
- 2024-10-28 JP JP2024189111A patent/JP2025010253A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532981A5 (enExample) | ||
| JP7395550B2 (ja) | 新規アデノ随伴ウイルスキャプシドタンパク質 | |
| US9540659B2 (en) | Modified adeno-associated virus vector compositions | |
| JP2022190081A5 (enExample) | ||
| FI3684423T3 (fi) | Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä | |
| JP2020019772A5 (enExample) | ||
| WO2016077687A4 (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
| JP2020519284A5 (enExample) | ||
| CA3158518A1 (en) | Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases | |
| CN120548368A (zh) | 用于正确包装重复元件的腺相关病毒载体 | |
| AU2022282057B2 (en) | Novel dual helper plasmid | |
| US20250283109A1 (en) | Plasmids and methods of production of adeno-associated viruses | |
| JPWO2020168222A5 (enExample) | ||
| JPWO2020186150A5 (enExample) | ||
| JPWO2020186207A5 (enExample) | ||
| CN120787264A (zh) | 肝脏去靶向衣壳 | |
| JPWO2021081236A5 (enExample) | ||
| RU2020109904A (ru) | МОДИФИЦИРОВАННАЯ ДНК С ЗАМКНУТЫМИ КОНЦАМИ (зкДНК) | |
| JPWO2021195218A5 (enExample) | ||
| JPWO2021195214A5 (enExample) | ||
| RU2024133098A (ru) | Направленная генная терапия для миотонической дистрофии dm-1 | |
| JPWO2020047268A5 (enExample) | ||
| JPWO2022061000A5 (enExample) | ||
| WO2025250909A1 (en) | Muscle-tropic recombinant aav | |
| CA3219287A1 (en) | Novel dual helper plasmid |